US 11,834,684 B2
Vaccine for immunocompromised hosts
Paula Maria Das Neves Ferreira Da Silva, Oporto (PT); and Pedro Jorge Fonseca Madureira, Oporto (PT)
Assigned to Universidade do Porto—Reitoria, Oporto (PT)
Filed by Universidade do Porto—Reitoria, Oporto (PT)
Filed on May 26, 2021, as Appl. No. 17/331,536.
Application 17/331,536 is a continuation of application No. 15/313,327, granted, now 11,066,652, previously published as PCT/EP2015/063243, filed on Jun. 12, 2015.
Claims priority of application No. 14398006 (EP), filed on Jun. 12, 2014; and application No. 15398003 (EP), filed on Mar. 30, 2015.
Prior Publication US 2022/0049229 A1, Feb. 17, 2022
Int. Cl. C12N 9/02 (2006.01); A01K 67/027 (2006.01); A61K 39/108 (2006.01); A61K 39/085 (2006.01); A61K 39/09 (2006.01); A61K 39/095 (2006.01); A61K 39/104 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC C12N 9/0008 (2013.01) [A01K 67/0275 (2013.01); A61K 39/0258 (2013.01); A61K 39/0266 (2013.01); A61K 39/085 (2013.01); A61K 39/092 (2013.01); A61K 39/095 (2013.01); A61K 39/104 (2013.01); C07K 16/40 (2013.01); C12Y 102/01012 (2013.01); A01K 2217/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55 (2013.01); A61K 2039/57 (2013.01); C07K 2317/76 (2013.01)] 2 Claims
 
1. An isolated peptide that has at least 95% amino acid sequence identity to any one of SEQ ID NOs: 26-33.